New state laws aim to clarify abortion bans. Doctors say it's not so simple.
Texas, Kentucky and Tennessee all passed laws this year ostensibly clarifying the scope of its abortion bans, a reaction to climbing sepsis rates and harrowing stories of patients who have suffered or died preventable deaths. Since June 2022, lawmakers in at least nine states have introduced such bills.
But doctors, attorneys and policy experts say that the laws being enacted will not solve the problems health providers have been forced to navigate since the end of Roe: The risk of being punished has deterred physicians, hospitals and health systems from providing consistent care, even when it is needed.
'The problem with these clarifying laws is they don't expand access under the law, they don't change the definitions, and they don't remove the legislative interference in the practice of medicine,' said Molly Meegan, chief legal officer and general counsel to the American College of Obstetricians and Gynecologists.
In Texas, a bill that awaits Republican Gov. Greg Abbott's signature ostensibly clarifies when the state's near-total abortion ban allows for the procedure, saying explicitly that physicians do not need to wait until a patient is in imminent danger of dying to perform an abortion. The bill also requires training for doctors and lawyers on the state's abortion law.
But lawmakers have made clear that the bill, crafted in consultation with Texas-based health professionals and abortion opponents, does not introduce new exceptions; Texas' ban does not allow for abortions in cases of rape, incest or fatal fetal anomaly. And if enacted, it would codify a Texas Supreme Court decision that found that the state's ban still applied even in cases with complications that could threaten a pregnant person's health.. Such was the case for Dallas woman Kate Cox, who experienced amniotic fluid leaking and cramping — which create the risk of bacterial infection — after discovering a likely-fatal fetal anomaly in her pregnancy.
Some former abortion patients whose lives were endangered because of delayed or denied care, including several who challenged the Texas abortion ban, said they fear Senate Bill 31 may not address situations like theirs.
Amanda Zurawski, who sued the state after being denied an abortion when experiencing a life-threatening condition called preterm premature rupture of membrane, said at a legislative hearing on the bill that it likely doesn't provide the clarity she would have needed.
'It is unclear whether SB 31 would have prevented my trauma and preserved my fertility had it existed in 2022, and I find that problematic,' Zurawski said. She only received care after she developed sepsis.
Clarification bills can have mixed support in legislatures. Local physicians might back tweaks to exemption language if they see it as potentially lifesaving for their patients. Some anti-abortion advocates might also favor changes if the legislation can address certain medical emergencies that they believe fall outside of a state's ban, such as ectopic pregnancies or preterm premature rupture of membranes.
But not all anti-abortion advocates or Republican lawmakers within these statehouses support even a small clarification.
'I think in all these cases, lawmakers are being pulled in different directions by these different constituencies,' said Mary Ziegler, an abortion law historian at the University of California, Davis. 'The bills themselves are kind of muddy, because they're trying to be different things to different people.'
The end result are clarification laws that remain unclear to physicians and their employing hospitals and health systems, who can still face high penalties for violating an abortion ban.
'When the law isn't clear, physicians don't intervene,' Ziegler said. 'You're not going to be willing to gamble your liberty and your medical license on an uncertain interpretation of the law.'
In Kentucky, doctors vocally opposed a Republican-backed bill that supporters said would help health professionals understand when they can provide abortions. Like in Texas, the state's ban only allows abortion when it is necessary to save a pregnant person's life. The clarification bill listed specific conditions that would qualify for an exception to the ban — such as sepsis, hemorrhage or ectopic pregnancy — despite concern from doctors that a delineated list wouldn't be able to predict every possible situation where an abortion might save someone's life.
Democratic Gov. Andy Beshear vetoed the bill in March, calling gaps in the law 'literally a matter of life and death.' The state's legislature, where the GOP holds a supermajority, voted days later to override him.
'It's hard to create this laundry list of, 'This is OK, this is not OK,' because unfortunately, medicine is something with a bunch of gray areas,' said Dr. Caitlin Thomas, an OB-GYN in Louisville.
In Georgia — where pregnant, brain-dead woman Adriana Smith remains on life-support until she can give birth later this summer, and where the death of Amber Thurman was attributed to the confusion created by the state's abortion ban — some lawmakers have asked physicians whether a clarification might allow doctors to provide abortions when the pregnancy threatens a patient's life, possibly by listing specific conditions that qualify for an exception.
'We encouraged them not to, and said that would not be helpful,' said Dr. Neesha Verma, an Atlanta-based OB-GYN. 'The more and more prescriptive you make these laws, the less space there is for clinical judgment.'
Following a case filed by seven Tennessee patients who had been denied abortions under the state's ban, lawmakers in that state passed a law this year meant to clarify that, under the state's ban, abortions could be performed in cases of preterm prelabor rupture of membrane or severe preeclampsia, but that the exception did not include mental health emergencies. Mental health conditions including substance use disorder, depression and confirmed or probably suicide are the largest single cause of pregnancy-related deaths in the state, according to a 2022 report.
The interest in clarifying bans — including from some lawmakers who oppose abortion — 'is a response to where we know the public is and the fact that we know the public is generally supportive of abortion access and also has been presented with these terrible preventable cases since Dobbs,' said Kimya Forouzan, who tracks state policy for the Guttmacher Institute, a nonprofit abortion research organization.
That ambiguity was on display in a Texas case last year. A state judge held that the state's abortion law exception permitted Cox to have an abortion when her doctors discovered the anomaly in her pregnancy. But the state's attorney general, Ken Paxton, swiftly intervened, threatening legal action against any health care provider that performed an abortion on Cox. Cox ultimately left the state to terminate her pregnancy.
Michele Goodwin, a law professor at the University of California, Irvine and author of 'Policing the Womb: Invisible Women and the Criminalization of Motherhood,' said state officials can do more to ensure health providers know their legal rights.
'It would be credible for states' attorneys generals and the prosecutors who are conservative to immediately issue statements of clarity, saying that they are opposed to these kinds of conditions, that they will not prosecute,' she said.
The post New state laws aim to clarify abortion bans. Doctors say it's not so simple. appeared first on The 19th.
News that represents you, in your inbox every weekday. Subscribe to our free, daily newsletter.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
29 minutes ago
- Business Wire
Priority Health Expands into Wisconsin by Becoming Governing Member of Group Health Cooperative of Eau Claire
BUSINESS WIRE)--Priority Health, a Michigan-based health plan serving more than 1.3 million members, and Group Health Cooperative of Eau Claire (the Cooperative), a community-based health plan in Wisconsin serving more than 61,000 members, have announced plans for Priority Health to become the governing member of the Cooperative. "By bringing together our strengths and capabilities, we are better positioned to improve health outcomes and provide an exceptional member experience." 'This agreement with Group Health Cooperative of Eau Claire marks a significant milestone in our mission to expand access to high-quality, affordable health care to those we are privileged to serve,' said Nick Gates, interim president of Priority Health. 'By bringing together our strengths and capabilities, we are better positioned to improve health outcomes and provide an exceptional member experience. We look forward to serving the members of Group Health Cooperative of Eau Claire.' Sarah North, CEO and general manager of Group Health Cooperative of Eau Claire, said: 'Priority Health brings a track record of thoughtful leadership and a deep commitment to improving health outcomes — qualities that align well with our values. This agreement lays the groundwork for continued growth and innovation in today's rapidly evolving health care landscape and positions us for long-term sustainability while allowing us to stay true to our purpose of improving health and offering community-based health plans in Wisconsin.' Both organizations anticipate the transaction will close by the end of 2025 after required approvals are completed. The agreement with the Cooperative will make Priority Health a four-state health plan. In December 2024, Priority Health became the sole member of Physicians Health Plan of Northern Indiana, which serves members in Indiana and Ohio. Kaufman, Hall, and Associates, LLC is serving as exclusive strategic and financial advisor and Weld Riley is serving as legal counsel to Group Health Cooperative Eau Claire in this transaction. Taft Stettinius & Hollister is serving as external legal counsel to Priority Health and Ankura is serving as due diligence advisor. About Priority Health: Our members are at the heart of everything we do. With more than 30 years in business, Priority Health is the second-largest health plan in Michigan and the third-largest provider-sponsored health plan in the nation, offering an extensive portfolio of health benefits options for employer groups and individuals, including Medicare and Medicaid plans. Serving more than 1.3 million members each year in Michigan, Indiana and Ohio, Priority Health offers a broad network of primary care physicians. Priority Health continues to be recognized as a leader for quality, customer service, transparency and product innovation. Learn more about affordable, quality health coverage options from Priority Health. Visit the Priority Health newsroom for the latest news. About Group Health Cooperative of Eau Claire: Founded in 1972, Group Health Cooperative of Eau Claire is a nonprofit, member-focused health plan serving approximately 61,000 members across Wisconsin, including Medicaid and Medicare beneficiaries, commercial employer groups, and state employees. Visit Group Health Cooperative of Eau Claire to learn more.
Yahoo
2 hours ago
- Yahoo
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
AUSTIN, Texas, July 24, 2025--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENSai™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human trials. "ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars," said Dr. Jennifer Bath, President & CEO, IPA. "With LENSai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules." Late‑stage ADA failures can wipe out $1–2 billion in projected revenue for a single biologic and push launch timelines back 12‑18 months. Yet many programs still lean on time‑intensive lab assays or first‑generation in‑silico screens that look only at peptide‑to‑MHC II binding across a few dozen HLA alleles—leaving large swaths of immune diversity untested and immunogenic "self/non‑self" checks largely unaddressed. LENSai's HYFT‑powered, alignment‑free immunogenicity screening compresses that entire workflow into one overnight run. It evaluates nearly 900 HLA variants and performs a whole‑proteome "humanness" scan at residue resolution, instantly flagging hot‑spots that legacy tools miss. By revealing design‑level fixes before expensive animal studies or repeat GMP production, the platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. Study Highlights 217 marketed and clinical-stage antibodies analyzed – the largest public ADA dataset to predict immunogenicity risk Single composite score tracks clinical reality – enables reliable ADA incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ADA in patients). The discriminative capability is very powerful as indicated by an AUC=0.92. Alignment-free, HYFT-powered engine – the proprietary screening algorithm combines state-of-the-art MHC II binding with IPA's proprietary HYFT® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments. Detailed amino acid and epitope-level immunogenicity "self" scanning – quickly pinpoints immunogenic hot-spots and suggests sequence edits before expensive wet-lab assays. Read the full case study: [link] About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. Forward-Looking Statements This press release contains forward looking statements within the meaning of applicable United States and Canadian securities laws. Forward looking statements are often identified by words such as "expects," "intends," "plans," "anticipates," "believes," "potential," or similar expressions, or by statements that certain actions, events, or results "may," "will," "could," or "might" occur or be achieved. Examples include statements regarding the projected performance, scalability, and market adoption of the Company's LENSai™ Immunogenicity Screening; the ability of its HYFT® powered, alignment free platform to shorten development timelines, reduce program risk, or displace legacy wet lab and multiple sequence alignment methods; the economic impact of early, in-silico ADA prediction on biopharma R&D efficiency; and the Company's broader scientific, commercial, and capital markets objectives. Forward looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results could differ materially from those expressed or implied because of factors beyond the Company's control, including the pace of scientific and technological innovation in AI driven drug discovery, the accuracy and regulatory acceptance of in-silico ADA risk screening, competitive shifts as the industry transitions away from MS dependent workflows, customer adoption rates, operational or integration challenges, and changes in economic, market, or regulatory conditions. Additional information about these and other risks and uncertainties is set out in the Company's Annual Report on Form 20F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at and EDGAR profile at If any of these risks materialize, the Company's actual results, performance, or achievements could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on forward looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. View source version on Contacts Investor Relations Contact Louie TomaManaging Director, CORE IRinvestors@
Yahoo
3 hours ago
- Yahoo
Here's What to Expect From Medtronic's Next Earnings Report
Galway, Ireland-based Medtronic plc (MDT) designs, manufactures, and distributes a wide range of medical devices, therapies, and digital health solutions used to treat chronic and complex health conditions across global healthcare systems. Valued at a market cap of $118 billion, the company is committed to advancing medical technology to alleviate pain, restore health, and extend life. It is scheduled to announce its fiscal Q1 earnings for 2026 before the market opens on Tuesday, Aug. 19. Before this event, analysts project this healthcare giant to report a profit of $1.23 per share, in line with the year-ago quarter. The company has surpassed Wall Street's bottom-line estimates in each of the last four quarters. Its earnings of $1.62 per share in the previous quarter outpaced the consensus estimates by 2.5%. More News from Barchart NVDA Broken Wing Butterfly Trade Targets A Profit Zone Between 150 and 160 Is Opendoor Stock a Buy at New 52-Week Highs? Billionaire Peter Thiel is Betting Big on Stablecoins. Should You Buy the "MicroStrategy of Ethereum," Too? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! For the full year, analysts expect MDT to report EPS of $5.55, up 1.1% from $5.49 per share in fiscal 2025. Furthermore, its EPS is expected to grow 7.9% year-over-year to $5.99 in fiscal 2027. MDT has rallied 15.9% over the past 52 weeks, outpacing both the S&P 500 Index's ($SPX) 14.5% uptick and the Health Care Select Sector SPDR Fund's (XLV) 8.3% drop over the same time frame. Despite delivering stronger-than-expected results, shares of Medtronic plunged 2.3% after its Q4 earnings release on May 21. The company's revenue improved 3.9% year-over-year to $8.9 billion, topping consensus estimates by 1.1%. Moreover, its adjusted EPS of $1.62 advanced nearly 11% from the year-ago quarter and came in 2.5% above the analyst expectations. Looking ahead to fiscal 2026, Medtronic expects adjusted EPS in the range of $5.50 to $5.60, and anticipates organic sales growth of approximately 5%. Wall Street analysts are moderately optimistic about MDT's stock, with an overall "Moderate Buy" rating. Among 30 analysts covering the stock, 13 recommend "Strong Buy," one indicates a "Moderate Buy," 15 advise 'Hold,' and one suggests a "Strong Sell' rating. The mean price target for Medtronic is $95.83, implying a 4.2% premium from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data